# Interferon-α After DLI for the Prevention of Relapse

> **NCT02568241** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **OTHER:** Interferon Alfa-2b

## Key facts

- **NCT ID:** NCT02568241
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2017-12
- **Final completion:** 2020-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02568241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02568241, "Interferon-α After DLI for the Prevention of Relapse". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02568241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*